Latest salvo in Pfizer activist fight; John Carroll's Q3 biotech roundup;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleNovartis pays Monte Rosa $150M for Phase 1 drug in latest endorsement of...
Novartis is getting a hold of one of Monte Rosa Therapeutics’ clinical-stage molecular glues, and it's putting more than $2.2 billion on the table. That includes $150 million upfront for MRT-6160,...
View ArticleFormer Seagen CEO David Epstein to lead new biotech with VEGF bifunctional...
David Epstein, who was the CEO of Seagen when it was acquired by Pfizer for $43 billion last year, is joining a new biotech that’s looking into one of the buzziest approaches ...
View ArticleSynaffix launches startup with pipeline of ADC drugs and $92M
The Dutch biotech Synaffix has long been one of the top partners for biopharma companies working in antibody-drug conjugates. Now the company is spinning out a pipeline of drugs into a new company....
View ArticleHOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning...
HOPO Therapeutics scored a government contract for up to $226 million to develop an oral countermeasure against radiological threats and heavy metal poisoning. The funding from the Biomedical Advanced...
View ArticleAbbVie makes $1.4B acquisition of Alzheimer's biotech
AbbVie said Monday it will pay $1.4 billion in cash to buy a Phase 1 Alzheimer's and neuroscience biotech, extending the company’s reach into CNS R&D and ...
View ArticleBiogen's full Ph2 data for IgA nephropathy drug; Sanofi invests in obesity...
Plus, news about Novartis, CombiGene, ProQR and Aardvark Therapeutics: Biogen presents full Phase 2 data for felzartamab: The drug, which was acquired in Biogen’s $1.15 billion buyout of HI-Bio earlier...
View ArticleBeiGene executive reportedly under investigation in China
Eva Yin, the chief commercial officer for Greater China at BeiGene, is reportedly under investigation by local authorities for alleged ties to an insurance fraud case while she was at AstraZeneca. The...
View ArticleLilly, J&J both unveil positive late-stage data in Crohn's disease
Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also sharing long-term data in ulcerative colitis. In the Phase 3 GRAVITI study,...
View ArticleBipartisan letter questions FDA's 'narrow' interpretation for priority review...
Sen. Tim Scott (R-SC) and Rep. Danny Davis (D-IL) are questioning the FDA's "narrow" interpretation of “active ingredient” when it comes to awarding the potentially lucrative priority review vouchers....
View ArticleWuXi AppTec is still signing on new clients despite Biosecure threat
WuXi AppTec said it is still attracting hundreds of fresh customers despite the Biosecure Act looming in the background. But a vast majority of these new clients are for early-stage services with...
View ArticleHow Nvidia plans to provide the building blocks of AI in health tech
LAS VEGAS — Nvidia’s ambitions within healthcare have a strong foothold in biopharma and life sciences. It’s now looking to grow its presence in digital health. The AI chipmaker’s healthcare strategy...
View ArticleIambic attempts to ‘break the wall’ between the lab and clinic with new AI model
Iambic Therapeutics has used its AI models to build a pipeline and put its first drug candidate in the clinic earlier this year. Now, the San Diego company is debuting a model with even bolder ...
View ArticleNovartis takes $800M MorphoSys writedown mere months after closing acquisition
Just five months after closing its $2.9 billion deal for MorphoSys, Novartis has recorded an $800 million impairment on the acquisition after a review of “certain clinical trial data,” the company said...
View ArticleCorrected: Genmab lines up T cell engager pact with Revitope
Genmab, a well-known Danish antibody biotech, is partnering with Revitope Oncology on T cell engagers, a type of cancer medicine that has become more popular this year and is now being tested in...
View ArticlePfizer raises revenue guidance by $1.5B amid activist pressure
Pfizer hasn’t escaped the volatility of its Covid-19 business — for better or worse. Making its first substantive comments on the activist investor pushing for changes at the company, Pfizer on Tuesday...
View ArticleParagon launches another company in hot PD-1xVEGF space that goes straight to...
Antibody maker Paragon Therapeutics has formed another company, this time in the bustling cancer space of PD-1xVEGF, and it will go straight onto the public markets. The new biotech, named Crescent...
View ArticlePathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AI
Chicago startup Pathos AI has completed a $62 million Series C to keep looking for Phase 1 cancer drugs that it can acquire and test in more specific patient populations, it
View Article